MARKET

DARE

DARE

Dare Bioscience Inc
NASDAQ
0.3059
+0.0167
+5.77%
After Hours: 0.3059 0 0.00% 18:36 04/26 EDT
OPEN
0.2880
PREV CLOSE
0.2892
HIGH
0.3084
LOW
0.2800
VOLUME
175.08K
TURNOVER
0
52 WEEK HIGH
1.100
52 WEEK LOW
0.2700
MARKET CAP
30.77M
P/E (TTM)
-0.8854
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's After-Market Session
Tevogen Bio Holdings (NASDAQ:TVGN) shares rose 51.8% to $1.29 during Thursday's after-market session. Fresh2 Group stock rose 10.61% and ResMed stock rose 6.85% in the same session. The company's Q3 earnings came out today.
Benzinga · 1d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Acrivon Therapeutics stock rose 12.3% to $10.67 during Wednesday's after-market session. The company's, Q1 earnings came out today. Amarin Corp stock moved upwards by 8.12% and Universe Pharmaceuticals stock rose 7.47% in the same session.
Benzinga · 2d ago
DARE BIOSCIENCE: TO GET $1 MLN AS LATEST INSTALLMENT UNDER GRANT DEAL TO ADVANCE DEVELOPMENT OF DARÉ'S INVESTIGATIONAL CONTRACEPTIVE DARE-LARC1
Reuters · 4d ago
DARE BIOSCIENCE: UNDER TERMS OF GRANT AGREEMENT, DARÉ MAY GET UP TO ABOUT $49 MLN TO SUPPORT NONCLINICAL DEVELOPMENT OF DARE-LARC1
Reuters · 4d ago
Press Release: Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience's DARE-LARC1 Platform Technology has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases. Daré will receive a payment of $1 million to support the development of the company's investigational contraceptive. The company is developing a long-acting, reversible contraceptive with precision dosing, extended device duration and wireless control. The technology could be used to treat diabetes, obesity and other conditions.
Dow Jones · 4d ago
Press Release: Daré Bioscience Announces Grant -2-
Failure or delay in starting, conducting and completing clinical trials of a product candidate; Daré's ability to design and conduct successful clinical trials. The risk that the FDA, other regulatory authorities and investors may not accept or agree with the results of clinical studies. Daré Bioscience's dependence on third parties to conduct clinical trials and commercialize its product candidates.
Dow Jones · 4d ago
Weekly Report: what happened at DARE last week (0415-0419)?
Weekly Report · 5d ago
Dare Bioscience Cut to Hold From Buy by Brookline Capital
Dow Jones · 04/17 17:38
More
About DARE
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.

Webull offers Dare Bioscience Inc stock information, including NASDAQ: DARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DARE stock methods without spending real money on the virtual paper trading platform.